William Blair analyst Andrew Brackmann has reiterated their bullish stance on BLLN stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Andrew Brackmann has given his Buy rating due to a combination of factors that highlight BillionToOne’s strong growth potential. The company’s recent earnings call underscored significant drivers of growth, particularly in the prenatal and oncology sectors, where increased test volumes and expanding average selling prices are contributing to robust performance. This momentum is expected to continue, with management projecting substantial revenue growth into 2025 and beyond.
Moreover, BillionToOne’s strategic plans to integrate with electronic medical records through Epic Aura are anticipated to enhance adoption rates in health systems, further boosting long-term revenue prospects. Brackmann’s analysis suggests that the company’s revenue could exceed current estimates, potentially leading to improved margins and positive operating income in the future. These factors collectively support a positive outlook for the stock, justifying the Buy rating.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $160.00 price target.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLLN in relation to earlier this year.